CYP2C19*2 and CYP2C19*17 polymorphisms in the treatment of schizophrenia

The treatment of schizophrenia, as a severe mental illness manifested through hallucinations and persistent delusions, with negative impacts on the personal, family and socio-economic lives of patients, has required from the scientific field important genetic and pharmacological interventions and research, since the effectiveness and efficiency of certain drugs is also associated with individual genetic variability.Studies have shown that more than 30% of schizophrenic patients do not respond effectively to clozapine, thus constituting the group of over-refrenquished patients. Given that CYP2C19 as a highly polymorphic enzyme has the second highest participation in clozapine metabolism, this paper aimed to evaluate the influences of CYP2C19*2 and CYP2C19*17 polymorphisms on the response to treatment with this antipsychotic in schizophrenia.In this line, it resulted that schizophrenic super-refrentive patients were mostly carriers of genetic CYP2C19*17 polymorphisms, associated with a higher daily dose of clozapine, but less efficient responses, since the presence of such a polymorphism makes them ultra-fast metabolic.